Keppra

Levetiracetam, the active ingredient in Keppra, is an anticonvulsant presented as an intravenous solution for intravenous use. It is employed to control partial seizures, generalized tonic‑clonic seizures, and myoclonic seizures in patients diagnosed with epilepsy.

GNH USA supplies Keppra as a licensed, GDP‑compliant international pharmaceutical product, providing the medication to hospitals, pharmacies and clinics worldwide, with a focus on EU‑regulated markets and adhering to stringent quality standards.

Levetiracetam (Keppra) is an anticonvulsant used in the management of epilepsy.

- Partial seizures: reduces frequency and severity of focal seizures. - Generalized tonic‑clonic seizures: helps prevent convulsive episodes. - Myoclonic seizures: decreases occurrence of sudden muscle jerks.

Levetiracetam may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Dizziness: transient sensation of light‑headedness. - Somnolence: increased sleepiness or fatigue. - Headache: mild to moderate cranial pain. - Nausea: occasional upset stomach. - Irritability: mood changes or agitation.

Serious or Rare Side Effects: - Severe skin reactions: rash, Stevens‑Johnson syndrome, or toxic epidermal necrolysis. - Psychiatric events: depression, suicidal thoughts, or aggressive behavior. - Hematologic abnormalities: low blood cell counts or anemia. - Respiratory depression: difficulty breathing, especially when combined with other CNS depressants.

When prescribing levetiracetam, clinicians should consider several precautionary measures to ensure safe use. - Renal impairment: assess kidney function and adjust therapy as needed. - Pregnancy: potential risks are not well defined; discuss benefits and alternatives with the patient. - Psychiatric symptoms: monitor for mood changes, depression, or suicidal ideation. - Concomitant CNS depressants: use caution as additive sedation may occur. - Discontinuation: avoid abrupt cessation; taper under medical supervision. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levetiracetam has a relatively low interaction profile, but certain drug combinations require attention.

Major Interactions (Avoid): - Combined use with other antiepileptic drugs that significantly depress central nervous system activity (e.g., phenobarbital) may increase sedation and respiratory risk. - Co‑administration with drugs known to cause severe hypersensitivity reactions (e.g., lamotrigine) may heighten the risk of serious skin disorders.

Moderate Interactions (Monitor Closely): - Concurrent nephrotoxic agents (e.g., aminoglycosides) may exacerbate renal impairment; monitor kidney function. - Alcohol or other CNS depressants: may enhance drowsiness or dizziness. - Hormonal contraceptives: levetiracetam may reduce efficacy; consider alternative or additional contraceptive methods.